조합 요법

• Main Authors: PACKMAN KATHRYN ELIZABETH, DASKALAKIS NIKKI, ALI AHMED SUMIA, LI MING, XU YANPING, THURING JOHANNES WILHELMUS J, DENG XIANGJUN, FANG LICHAO, DAI XUEDONG, KWON MIN CHUL, PANDE VINEET, PIETSCH EVA CHRISTINE, LIU YINGTAO, GUTTKE CHRISTINA DIANE, VERHULST TINNE ANN J, QUEROLLE OLIVIER ALEXIS GEORGES, FU LIQIANG, NG ALICIA TEE FUAY, SUN YU, FERRANTE LUCILLE ANGELA, PHILIPPAR ULRIKE, BHOGAL BALPREET, LIU LIANZHU, DARVILLE NICOLAS FREDDY J, CAI WEI
• Format: Patent
• Language: Korean
• Published: 15.01.2024
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

치료적 유효량의 화학식 (I)의 메닌-MLL 억제제 또는 이의 약제학적으로 허용되는 염 또는 용매화물; 및 저메틸화제, 시티딘 탈아미노효소 억제제, DNA 삽입제, 피리미딘 유사체, 퓨린 유사체, 키나제 억제제, CD20 억제제, IDH 억제제, 면역조절제 또는 DHODH 억제제인 치료적 유효량의 적어도 하나의 다른 치료제를 포함하는 조합물이 개시된다. 또한 이러한 조합물을 사용하는 암으로 진단받은 대상체를 치료하기 위한 방법이 개시된다. 화합물은 다음과 같은 화학식 (I)로 나타낸다:상기 식에서, R1a, R1b, R2,R3, R4, U, Y1,X1,X2, n1, n2, n3 및 n4는 본 명세서에 정의된다. JPEGpct00274.jpg4866 Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of at least one other therapeutic agent which is a hypomethylating agent, a cytidine deaminase inhibitor, a DNA intercalating agent, a pyrimidine analog, a purine analog, a kinase inhibitor, a CD20 inhibitor, an IDH inhibitor, an immunomodulatory agent or a DHODH inhibitor. Also disclosed are methods for treating a subject who has been diagnosed with cancer using such combinations. Compounds are represented by Formula (I) as follows:wherein R1a, R1b, R2, R3, R4, U, Y1, X1, X2, n1, n2, n3 and n4 are defined herein.